Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia

Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a therapeutic challenge. Loncastuximab tesirine is an antibody-drug conjugate against CD19, an antigen expressed in many B-cell malignancies. This open-label, single-arm, dose-escalation, dose-expansion study assessed t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Jain, Nitin, Stock, Wendy, Zeidan, Amer, Atallah, Ehab, McCloskey, James, Heffner, Leonard, Tomlinson, Benjamin, Bhatnagar, Bhavana, Feingold, Jay, Ungar, David, Chao, Grace, Zhang, Xiaoyan, Qin, Yajuan, Havenith, Karin, Kantarjian, Hagop, Wieduwilt, Matthew J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013258/
https://ncbi.nlm.nih.gov/pubmed/32012214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000767
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados